Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
AIDS Res Hum Retroviruses
    February 2024
  1. LAUFER N, Bouzas MB, Fernandez-Giuliano S, Zapiola I, et al
    Pretreatment HIV-1 Resistance in Argentina: results from the second surveillance study following WHO guidelines (2019).
    AIDS Res Hum Retroviruses. 2024 Feb 22. doi: 10.1089/AID.2023.0083.
    >> Share

    January 2024
  2. MANGALA C, Maulot-Bangola D, Moutsinga A, Wamba AG, et al
    CURRENT RESISTANCE OF HIV-1 STRAINS ISOLATED IN VOLUNTEER BLOOD DONORS IN GABON.
    AIDS Res Hum Retroviruses. 2024 Jan 2. doi: 10.1089/AID.2023.0080.
    >> Share

    December 2023
  3. PUJARI S, Gaikwad S, Panchawagh S, Chitalikar A, et al
    Effectiveness, weight changes and metabolic outcomes on switch to generic dolutegravir/lamivudine amongst people with HIV in Western India: An observational study.
    AIDS Res Hum Retroviruses. 2023 Dec 8. doi: 10.1089/AID.2022.0167.
    >> Share

    July 2023
  4. FARINACCI D, Iannone V, D'Angelillo A, Borghetti A, et al
    TWO-DRUG REGIMEN CONTAINING DARUNAVIR. METABOLIC EVALUATION OF AN OLD DUAL THERAPY.
    AIDS Res Hum Retroviruses. 2023 Jul 6. doi: 10.1089/AID.2023.0023.
    >> Share

    June 2023
  5. CALZA L, Colangeli V, Legnani G, Cretella S, et al
    EFFICACY AND SAFETY OF SWITCHING TO DOLUTEGRAVIR/LAMIVUDINE IN VIROLOGICALLY SUPPRESSED PEOPLE LIVING WITH HIV-1 AGED OVER 65 YEARS.
    AIDS Res Hum Retroviruses. 2023 Jun 19. doi: 10.1089/AID.2023.0046.
    >> Share

  6. LEE EH, Lee JA, Kim CH, Lee KH, et al
    Pentraxin 3 as an immune recovery marker in HIV infection after combination antiretroviral therapy.
    AIDS Res Hum Retroviruses. 2023 Jun 19. doi: 10.1089/AID.2023.0002.
    >> Share

  7. PATEL Y, Doshi A, Levesque A, Lindor S, et al
    Weight Gain in People with HIV: The role of demographics, antiretroviral therapy, and lifestyle factors on weight.
    AIDS Res Hum Retroviruses. 2023 Jun 5. doi: 10.1089/AID.2023.0008.
    >> Share

    May 2023
  8. CAO B, Liu M, Jiang T, Yu Q, et al
    HIV-1 RNA and DNA genotyping drug resistance detection in patients with low-level viremia in Liangshan, China.
    AIDS Res Hum Retroviruses. 2023 May 14. doi: 10.1089/AID.2022.0140.
    >> Share

  9. LAHIRI CD, Mehta CC, Sykes C, Weiser SD, et al
    Obesity Modifies the Relationship Between Raltegravir and Dolutegravir Hair Concentrations and Body Weight Gain in Women Living with HIV.
    AIDS Res Hum Retroviruses. 2023 May 4. doi: 10.1089/AID.2022.0185.
    >> Share

    April 2023
  10. PEREZ BARRAGAN E, Guevara Maldonado MF, Mancilla Galindo J, Kammar Garcia A, et al
    Weight gain after 12 months of switching to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV patients.
    AIDS Res Hum Retroviruses. 2023 Apr 18. doi: 10.1089/AID.2022.0130.
    >> Share

  11. ATKINSON B, Abbasi A, Sajadi MM, Tehrani ZR, et al
    Replacement of ART with HIV Broadly Neutralizing Antibodies to Maximize the Effectiveness of Chemotherapy in HIV Patients with Lung Cancer.
    AIDS Res Hum Retroviruses. 2023 Apr 13. doi: 10.1089/AID.2022.0181.
    >> Share

  12. DU R, Huang J
    Machine learning revealed a novel ferroptosis-based classification for diagnosis in antiretroviral therapy-treated HIV patients with defective immune recovery.
    AIDS Res Hum Retroviruses. 2023 Apr 8. doi: 10.1089/AID.2022.0138.
    >> Share

    February 2023
  13. OOMEN PGA, Hakkers CS, Arends J, van den Berk G, et al
    The effect of efavirenz on reward processing in asymptomatic people living with HIV: a randomized controlled trial.
    AIDS Res Hum Retroviruses. 2023 Feb 3. doi: 10.1089/AID.2022.0069.
    >> Share

    January 2023
  14. BELAUNZARAN-ZAMUDIO PF, Naranjo L, Caro-Vega Y, Castillo-Mancilla JR, et al
    Incomplete ART Adherence Is Associated with Lower CD4-CD8 Ratio in Virally Suppressed Patients with HIV-infection in Mexico.
    AIDS Res Hum Retroviruses. 2023 Jan 3. doi: 10.1089/AID.2021.0179.
    >> Share

    December 2022
  15. WALMSLEY S, Clarke R, Lee T, Singer J, et al
    BEING: Bone Health in Aging Women with HIV: Impact of Switching Antiretroviral Therapy on Bone Mineral Density During the Peri-menopausal period.
    AIDS Res Hum Retroviruses. 2022 Dec 13. doi: 10.1089/AID.2022.0106.
    >> Share

  16. MISHRA S, Taneja S, De A, Verma N, et al
    Efficacy, tolerability and compliance of direct acting antivirals in patients with HIV and Hepatitis C co-infection: A real-life experience.
    AIDS Res Hum Retroviruses. 2022 Dec 13. doi: 10.1089/AID.2022.0034.
    >> Share

    November 2022
  17. LEAL L, Guardo AC, Bedoya LM, Rodriguez de Miguel C, et al
    Pharmacokinetics, the immunological impact and the effect on HIV ex-vivo infectivity of maraviroc, raltegravir and lopinavir in MSM using Post-exposure Prophylaxis.
    AIDS Res Hum Retroviruses. 2022 Nov 23. doi: 10.1089/AID.2021.0232.
    >> Share

  18. MOSCHOPOULOS C, Protopapas K, Thomas K, Kavatha D, et al
    Switching from tenofovir disoproxil to tenofovir alafenamide fumarate: Impact on cardiovascular risk and lipid profile in people living with HIV, an observational single-center study.
    AIDS Res Hum Retroviruses. 2022 Nov 18. doi: 10.1089/AID.2022.0086.
    >> Share

  19. FAILLA M, Pasquali E, Galli L, Chiappini E, et al
    Integrase strand transfer inhibitors use in children with perinatal HIV-1 infection: a narrative review.
    AIDS Res Hum Retroviruses. 2022 Nov 9. doi: 10.1089/AID.2022.0039.
    >> Share

    October 2022
  20. ADACHI E, Ikeuchi K, Koga M, Yotsuyanagi H, et al
    Changes in inflammatory biomarkers when switching from from 3-drug regimens to dolutegravir plus lamivudine in people living with HIV.
    AIDS Res Hum Retroviruses. 2022 Oct 27. doi: 10.1089/AID.2022.0115.
    >> Share

  21. ANDRADE A, Fuchs EJ, Marzinke MA, Abdul Massih S, et al
    EVG/COBI/FTC/TAF BIOEQUIVALENCE COMPARING WHOLE TABLETS TO TABLETS DISSOLVED IN TAP WATER.
    AIDS Res Hum Retroviruses. 2022 Oct 27. doi: 10.1089/AID.2022.0085.
    >> Share

  22. GRINSTEINER E, Morrow M, MaWhinney S, Coyle R, et al
    Demographic and clinical characteristics of persons with HIV with viral load:adherence mismatch who are at risk of future viremia.
    AIDS Res Hum Retroviruses. 2022 Oct 27. doi: 10.1089/AID.2021.0218.
    >> Share

  23. ZHOU XY, Li CX, Zhang JB, Tan JT, et al
    Association of human leukocyte antigen alleles and hypersensitivity of Efavirenz/Nevirapine in HIV-infected Chinese patients.
    AIDS Res Hum Retroviruses. 2022 Oct 13. doi: 10.1089/AID.2022.0027.
    >> Share

    September 2022
  24. ZHAO R, Ma R, Zhao C, Zhang Q, et al
    Risk factors for Osteonecrosis of the femoral head in HIV positive patients: A retrospective case-control study.
    AIDS Res Hum Retroviruses. 2022 Sep 27. doi: 10.1089/AID.2021.0224.
    >> Share

    August 2022
  25. KOUAMOU V, Machekano R, Mapangisana T, Maposhere C, et al
    Tenofovir, Lamivudine and Dolutegravir (TLD) among Rural Adolescents in Zimbabwe, a Cautionary Tale.
    AIDS Res Hum Retroviruses. 2022 Aug 12. doi: 10.1089/AID.2021.0140.
    >> Share

  26. YAGER J, Brooks KM, Brothers J, Mulligan K, et al
    Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate among transgender adolescents and young adults without HIV receiving gender affirming hormones.
    AIDS Res Hum Retroviruses. 2022 Aug 9. doi: 10.1089/AID.2022.0043.
    >> Share

  27. HSU R, Brunet L, Fusco JS, Mounzer K, et al
    Excessive weight gain: current antiretroviral agents in virologically suppressed people with HIV.
    AIDS Res Hum Retroviruses. 2022 Aug 3. doi: 10.1089/AID.2021.0188.
    >> Share

    July 2022
  28. YAGER J, Brooks KM, Brothers J, Mulligan K, et al
    Gender-affirming hormone pharmacokinetics among adolescent and young adult transgender persons receiving daily F/TDF.
    AIDS Res Hum Retroviruses. 2022 Jul 10. doi: 10.1089/AID.2022.0044.
    >> Share

  29. SIDDIQUI M, Moore TJ, Long DM, Burkholder GA, et al
    Risk factors for incident hypertension within one year of initiating antiretroviral therapy among people with HIV.
    AIDS Res Hum Retroviruses. 2022 Jul 1. doi: 10.1089/AID.2021.0213.
    >> Share

  30. TOEQUE MG, Lindsay B, Zulu PM, Hachaambwa L, et al
    Treatment-Experienced Patients on Third-Line Therapy: A Retrospective Cohort of Treatment Outcomes at the HIV Advanced Treatment Centre, University Teaching Hospital, Zambia.
    AIDS Res Hum Retroviruses. 2022 Jul 1. doi: 10.1089/AID.2021.0208.
    >> Share

    April 2022
  31. NARVAEZ M, Lins-Kusterer L, Valdelamar-Jimenez J, Brites C, et al
    Quality of life and antiretroviral therapy adherence: A cross-sectional study in Colombia.
    AIDS Res Hum Retroviruses. 2022 Apr 22. doi: 10.1089/AID.2021.0233.
    >> Share

    March 2022
  32. RUBIN L, Neijna A, Shi Q, Hoover DR, et al
    Degree of polypharmacy and cognitive function in older women with HIV.
    AIDS Res Hum Retroviruses. 2022 Mar 31. doi: 10.1089/AID.2021.0231.
    >> Share

  33. RUIZ-ALGUERO M, Alejos B, Garcia Yubero C, Riera Jaume M, et al
    Use of generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection in Spain.
    AIDS Res Hum Retroviruses. 2022 Mar 31. doi: 10.1089/AID.2021.0122.
    >> Share

  34. KARUNAIANANTHAM R, Nesakumar M, Gopalan B, Haribabu H, et al
    Molecular characterisation of the pol gene of vertically transmitted HIV-1 strains in children with virological failure.
    AIDS Res Hum Retroviruses. 2022 Mar 18. doi: 10.1089/AID.2021.0227.
    >> Share

  35. MCLIGEYO A, Wekesa P, Owuor K, Mwangi J, et al
    Factors associated with treatment outcomes among children and adolescents living with HIIV receiving antiretroviral therapy in central Kenya.
    AIDS Res Hum Retroviruses. 2022 Mar 1. doi: 10.1089/AID.2021.0112.
    >> Share

    February 2022
  36. TARAMASSO L, Lo Caputo S, Magnasco L, Briano F, et al
    Long-term effectiveness of rilpivirine-based single-tablet regimens in a seven-year two centers observational cohort of people living with HIV.
    AIDS Res Hum Retroviruses. 2022 Feb 16. doi: 10.1089/AID.2021.0161.
    >> Share

    December 2021
  37. SHIKUMA C, Le T, Phuong TV, Chew GM, et al
    Immunologic Change over 72 Weeks following Raltegravir- vs Efavirenz-based Therapy in HIV/HCV co-infected Individuals in Vietnam.
    AIDS Res Hum Retroviruses. 2021 Dec 3. doi: 10.1089/AID.2021.0076.
    >> Share

    November 2021
  38. JENNINGS L, Kellermann T, Spinelli MA, Nkantsu Z, et al
    Drug resistance, rather than low tenofovir levels in blood or urine, is associated with tenofovir, emtricitabine and efavirenz (TEE) failure in resource-limited settings.
    AIDS Res Hum Retroviruses. 2021 Nov 13. doi: 10.1089/AID.2021.0135.
    >> Share

    October 2021
  39. WALLNER J, Beck IA, Panpradist N, Ruth PS, et al
    Rapid, Near Point-of-Care Assay for HLA-B*57:01 Genotype Associated with Severe Hypersensitivity Reaction to Abacavir.
    AIDS Res Hum Retroviruses. 2021 Oct 29. doi: 10.1089/AID.2021.0103.
    >> Share

  40. PEREIRA B, Mazzitelli M, Milinkovic A, Moyle G, et al
    Predictive value of HIV-related versus traditional risk factors for coronary atherosclerosis in people aging with HIV.
    AIDS Res Hum Retroviruses. 2021 Oct 15. doi: 10.1089/AID.2021.0064.
    >> Share

    September 2021
  41. MCGOWAN IM, Kunjara Na Ayudhya RP, Brand RM, Marzinke MA, et al
    An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine / Tenofovir Disoproxil Fumarate.
    AIDS Res Hum Retroviruses. 2021 Sep 20. doi: 10.1089/AID.2021.0115.
    >> Share

    August 2021
  42. ARANCON PARDO A, Moreno Palomino M, Jimenez-Nacher I, Moreno F, et al
    REAL-WORLD EXPERIENCE WITH TWO-DRUG REGIMENS IN HIV-1 INFECTED PATIENTS BEYOND THE INDICATION OF CLINICAL TRIALS: 48 WEEKS RESULTS.
    AIDS Res Hum Retroviruses. 2021 Aug 31. doi: 10.1089/AID.2021.0041.
    >> Share

  43. MCGOWAN IM, Chawki S, Hendrix CW, Anton PA, et al
    A Randomized, Open Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study).
    AIDS Res Hum Retroviruses. 2021 Aug 12. doi: 10.1089/AID.2021.0096.
    >> Share

    May 2021
  44. MOUNZER K, Brunet L, Hsu R, Fusco JS, et al
    Changes in BMI associated with antiretroviral regimen switch among treatment-experienced, virologically suppressed people living with HIV in the United States.
    AIDS Res Hum Retroviruses. 2021 May 18. doi: 10.1089/AID.2020.0287.
    >> Share

    April 2021
  45. ROMANO JW, Baum M, Demkovich ZR, Diana F, et al
    Tenofovir Alafenamide (TAF) for HIV Prevention: Review of the Proceedings from the Gates Foundation Long Acting (LA) TAF Product Development Meeting.
    AIDS Res Hum Retroviruses. 2021 Apr 29. doi: 10.1089/AID.2021.0028.
    >> Share

  46. SIYAN C, Qihua X, Jian W, Xinghua T, et al
    Effects of artesunate tablet on immune activation and reconstitution among HAART-treated patients with incomplete immune responses.
    AIDS Res Hum Retroviruses. 2021 Apr 29. doi: 10.1089/AID.2020.0254.
    >> Share

    March 2021
  47. LOFGREN SM, Nicol MR, Kandole TK, Castillo-Mancilla JR, et al
    A Descriptive Analysis of Dried Blood Spot Adherence Testing Among Ugandans with HIV Presenting with Cryptococcal Meningitis.
    AIDS Res Hum Retroviruses. 2021 Mar 7. doi: 10.1089/AID.2020.0202.
    >> Share

    February 2021
  48. MILIC J, Novella A, Meschiari M, Menozzi M, et al
    Darunavir/cobicistat is associated with negative outcomes in HIV-negative patients with severe COVID-19 pneumonia.
    AIDS Res Hum Retroviruses. 2021 Feb 23. doi: 10.1089/AID.2020.0305.
    >> Share

  49. DA SILVA AS, Cavalcanti MDSM, Belmont TFM, Ximenes RAA, et al
    The 1G/1G + 1G/2G genotypes of MMP1 rs1799750 are associated with higher levels of MMP-1 and are both associated with lipodystrophy in people living with HIV on antiretroviral therapy?
    AIDS Res Hum Retroviruses. 2021 Feb 15. doi: 10.1089/AID.2020.0237.
    >> Share

  50. CICCULLO A, Baldin G, Borghi V, Lassandro AP, et al
    Lamivudine plus dolutegravir improves bone mineral density compared to emtricitabine/tenofovir alafenamide plus an integrase inhibitor.
    AIDS Res Hum Retroviruses. 2021 Feb 15. doi: 10.1089/AID.2020.0274.
    >> Share

  51. CICCULLO A, Baldin G, Dusina A, Cossu MV, et al
    Efficacy and safety of dolutegravir plus lamivudine as a first-line regimen in clinical practice.
    AIDS Res Hum Retroviruses. 2021 Feb 15. doi: 10.1089/AID.2020.0276.
    >> Share

  52. YORK L, Fisher JM, Malladi L, August JA, et al
    Antiretroviral Laboratory Monitoring and Implications for HIV Clinical Care in the Era of COVID-19 and Beyond.
    AIDS Res Hum Retroviruses. 2021 Feb 10. doi: 10.1089/AID.2020.0263.
    >> Share

  53. HU M, Valicherla GR, Zhou T, Hillier SL, et al
    Expression, activity, and regulation of phosphorylating enzymes in tissues and cells relevant to HIV-1 sexual transmission.
    AIDS Res Hum Retroviruses. 2021 Feb 10. doi: 10.1089/AID.2020.0250.
    >> Share

    January 2021
  54. CHAWANA TD, Nhachi CFB, Nathoo K, Ngara B, et al
    Higher tenofovir concentrations in hair are associated with decreases in viral load and not self-reported adherence in HIV-infected adolescents with second line virological treatment failure.
    AIDS Res Hum Retroviruses. 2021 Jan 26. doi: 10.1089/AID.2020.0258.
    >> Share

  55. HAALAND R, Martin A, Mengesha M, Dinh C, et al
    Evaluation of antiretroviral drug concentrations in minimally invasive specimens for potential development of point of care drug assays.
    AIDS Res Hum Retroviruses. 2021 Jan 18. doi: 10.1089/AID.2020.0187.
    >> Share

  56. KOUAMOU V, Mavetera J, Manasa J, Ndhlovu CE, et al
    Pre-treatment HIV Drug Resistance Among Adults Initiating or Re-initiating 1st Line Antiretroviral Therapy in Zimbabwe: Fast-tracking the Transition to Dolutegravir Based 1st Line Regimens?
    AIDS Res Hum Retroviruses. 2021 Jan 11. doi: 10.1089/AID.2020.0242.
    >> Share

  57. BARIK SK, Bansal AK, Mohanty PS, Tripathy SP, et al
    Detection of drug resistance mutations in the reverse transcriptase gene of HIV-1-infected North Indian population failing first line antiretroviral therapy "A follow-up cohort study".
    AIDS Res Hum Retroviruses. 2021 Jan 3. doi: 10.1089/AID.2020.0132.
    >> Share

    December 2020
  58. BORGHETTI A, Bellino S, Lombardi F, Whalen M, et al
    Risk of tumour onset in HIV+ patients on two-drug regimens: a cohort study in an Italian hospital.
    AIDS Res Hum Retroviruses. 2020 Dec 15. doi: 10.1089/AID.2020.0087.
    >> Share

  59. LAN Y, Li L, Deng X, Cai X, et al
    Near full-length genomic characterization of a novel HIV-1 B/C recombinant form identified in Guangdong Province, China.
    AIDS Res Hum Retroviruses. 2020 Dec 7. doi: 10.1089/AID.2020.0278.
    >> Share

  60. BALDIN G, Ciccullo A, Lombardi F, D'Angelillo A, et al
    Comparing lamivudine+dolutegravir and bictegravir/emtricitabine/tenofovir alafenamide as switch strategies: preliminary results from clinical practice.
    AIDS Res Hum Retroviruses. 2020 Dec 5. doi: 10.1089/AID.2020.0219.
    >> Share

    November 2020
  61. MEHTA G, Sharma A, Arora SK
    Human Immunodeficiency virus-1 (HIV-1) subtype-C genetically diversify to acquire higher replication competence in human host with co-morbid conditions.
    AIDS Res Hum Retroviruses. 2020 Nov 25. doi: 10.1089/AID.2020.0118.
    >> Share

  62. LAHIRI C, Xu Y, Wang K, Alvarez JA, et al
    Weight and body mass index change after switching to integrase inhibitors or tenofovir alafenamide among women living with HIV.
    AIDS Res Hum Retroviruses. 2020 Nov 24. doi: 10.1089/AID.2020.0197.
    >> Share

  63. IBRAHIM ME, Castillo-Mancilla JR, Yager J, Brooks KM, et al
    Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis.
    AIDS Res Hum Retroviruses. 2020 Nov 15. doi: 10.1089/AID.2020.0108.
    >> Share

    October 2020
  64. PARKER I, Khalil G, Martin A, Martin MT, et al
    Altered Antibody Responses in Persons Infected with HIV-1 While Using PrEP.
    AIDS Res Hum Retroviruses. 2020 Oct 30. doi: 10.1089/AID.2020.0137.
    >> Share

  65. CALZA L, Borderi M, Colangeli V, Testi D, et al
    NO SIGNIFICANT CHANGES IN WEIGHT AND BODY FAT MASS IN SUPPRESSED HIV-INFECTED PATIENTS SWITCHED TO DUAL COMBINATION LAMIVUDINE PLUS DOLUTEGRAVIR OR RALTEGRAVIR.
    AIDS Res Hum Retroviruses. 2020 Oct 30. doi: 10.1089/AID.2020.0117.
    >> Share

  66. SRINIVASAN R, Padmapriyadarsini C, Ramesh K, Sanjeeva GN, et al
    APOC3 Gene polymorphism and ART-induced dyslipidemia in HIV Infected Children.
    AIDS Res Hum Retroviruses. 2020 Oct 29. doi: 10.1089/AID.2020.0082.
    >> Share

  67. GHOSN J, Abdoul H, Fellahi S, Merlet A, et al
    Prevalence of silent atherosclerosis and other comorbidities in an outpatient cohort of adults living with HIV: associations with HIV parameters and biomarkers.
    AIDS Res Hum Retroviruses. 2020 Oct 20. doi: 10.1089/AID.2020.0182.
    >> Share

  68. MEISSNER EG, Chung D, Tsao B, Haas D, et al
    IFNL4 Genotype Does Not Associate with CD4 T-Cell Recovery in Persons Living with HIV.
    AIDS Res Hum Retroviruses. 2020 Oct 16. doi: 10.1089/AID.2020.0104.
    >> Share

  69. LOUTFY M, Varriano B, Crouzat F, Sandler I, et al
    Cardiovascular events in an inner-city HIV clinic and relation to abacavir- vs. TDF- containing antiretroviral regimens.
    AIDS Res Hum Retroviruses. 2020 Oct 6. doi: 10.1089/AID.2020.0053.
    >> Share

    September 2020
  70. CICCULLO A, Baldin G, Borghi V, Sterrantino G, et al
    Overall tolerability of Integrase Inhibitors in clinical practice: results from a multicenter Italian cohort.
    AIDS Res Hum Retroviruses. 2020 Sep 30. doi: 10.1089/AID.2020.0078.
    >> Share

  71. MOYO T, Guleid FH, Schomaker M, Williamson C, et al
    HIV-1 Subtype C tier 3 viruses have increased infectivity as compared to tier 2 viruses.
    AIDS Res Hum Retroviruses. 2020 Sep 16. doi: 10.1089/AID.2020.0124.
    >> Share

  72. CALZA L, Borderi M, Colangeli V, Esposito F, et al
    NO SIGNIFICANT INCREASE IN BODY FAT MASS IN NAIVE HIV-INFECTED PATIENTS STARTING RALTEGRAVIR PLUS TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE.
    AIDS Res Hum Retroviruses. 2020 Sep 16. doi: 10.1089/AID.2020.0167.
    >> Share

  73. LAN Y, He X, Xin R, Li L, et al
    Genetic characteristics of CRF12_BF first identified in Guangdong Province, China.
    AIDS Res Hum Retroviruses. 2020 Sep 1. doi: 10.1089/AID.2020.0193.
    >> Share

    July 2020
  74. OKHAI H, Vivancos Gallego MJ, Hill T, Sabin CA, et al
    CD4+:CD8+ T-cell ratio normalisation and the development of AIDS events in people with HIV starting antiretroviral therapy.
    AIDS Res Hum Retroviruses. 2020 Jul 14. doi: 10.1089/AID.2020.0106.
    >> Share

  75. MIKASI SG, Isaacs D, Ikomey GM, Shimba H, et al
    HIV-1 drug resistance mutation analyses of Cameroon derived Integrase sequences.
    AIDS Res Hum Retroviruses. 2020 Jul 8. doi: 10.1089/AID.2020.0022.
    >> Share

  76. WEICHSELDORFER M, Affram Y, Heredia A, Tagaya Y, et al
    Anti-HIV Activity of Standard cART in Primary Cells Is Intensified by CCR5-Targeting Drugs.
    AIDS Res Hum Retroviruses. 2020 Jul 5. doi: 10.1089/AID.2020.0064.
    >> Share

    June 2020
  77. PETRAKIS V, Panagopoulos P, Papachristou S, Papanas N, et al
    Tenofovir alafenamide fumarate therapy for HIV treatment: Cardiometabolic and renal safety.
    AIDS Res Hum Retroviruses. 2020 Jun 11. doi: 10.1089/AID.2019.0280.
    >> Share

  78. DABEE S, Mkhize NN, Jaspan HB, Lewis D, et al
    Initiation of antiretroviral therapy differentially influences genital and systemic immune activation in HIV-infected women.
    AIDS Res Hum Retroviruses. 2020 Jun 11. doi: 10.1089/AID.2019.0268.
    >> Share

    May 2020
  79. DIGBAN T, Iweriebor B, Nwodo UU, Okoh AI, et al
    Chemokine Coreceptor Usage among HIV-1 treatment Inexperienced Patients residing in the Rural Eastern Cape, South Africa.
    AIDS Res Hum Retroviruses. 2020 May 29. doi: 10.1089/AID.2020.0066.
    >> Share

  80. MIKULA T, Sapula M, Suchacz M, Kozlowska J, et al
    Risk Factors of Hypovitaminosis D in HIV-Infected Patients on Suppressive Antiretroviral Therapy.
    AIDS Res Hum Retroviruses. 2020 May 14. doi: 10.1089/AID.2019.0020.
    >> Share

  81. MARTIN IB, Read S, Harrigan PR, Gomez P, et al
    Treatment experience and repeat pregnancy impacts the effectiveness of NNRTI-HAART for the prevention of mother to child transmission of HIV.
    AIDS Res Hum Retroviruses. 2020 May 14. doi: 10.1089/AID.2019.0001.
    >> Share

  82. NICOL M, Cottrell M, Corbett A, Chinula L, et al
    Endogenous hormones and anitretroviral exposure in plasma, cervicovaginal fluid, and upper-layer packed cells of Malawian women living with HIV.
    AIDS Res Hum Retroviruses. 2020 May 10. doi: 10.1089/AID.2019.0278.
    >> Share

  83. DONG A, Liu L, Xiao L, Liang S, et al
    First Detection of a Circulating Recombinant Form of HIV-1 CRF01_AE/08_BC (CRF105_0108) with Drug-Resistant Mutations in Sichuan, China.
    AIDS Res Hum Retroviruses. 2020 May 6. doi: 10.1089/AID.2020.0034.
    >> Share

  84. SABERI P, Eskaf S, Sauceda J, Evans D, et al
    Perceptions of HIV Virologic Control Strategies among Younger and Older Age Groups of People Living with HIV in the United States: A Cross-Sectional Survey.
    AIDS Res Hum Retroviruses. 2020 May 5. doi: 10.1089/AID.2020.0023.
    >> Share

    April 2020
  85. ASHURO AA, Lobie TA, Ye DQ, Leng RX, et al
    Review on the alteration of gut microbiota: the role of HIV infection and old age.
    AIDS Res Hum Retroviruses. 2020 Apr 23. doi: 10.1089/AID.2019.0282.
    >> Share

    March 2020
  86. MYSIOR P, Tenberken E, Stecher M, Vehreschild JJ, et al
    Rapid Uptake of Pre-Exposure Prophylaxis (PrEP) after Significant Price Reduction in Germany Highlights Importance of PrEP Accessibility.
    AIDS Res Hum Retroviruses. 2020 Mar 13. doi: 10.1089/AID.2019.0237.
    >> Share

  87. EMILOVA R, Manolov V, Todorova Y, Yancheva N, et al
    Elevated Labile Iron Levels in CD4 and CD8 T Cells From HIV Positive Individuals With Undetectable Viral Load.
    AIDS Res Hum Retroviruses. 2020 Mar 13. doi: 10.1089/AID.2020.0010.
    >> Share

  88. KOUAMOU V, Varyani B, Shamu T, Mapangisana T, et al
    Drug Resistance among Adolescents and Young Adults with Virologic Failure of First Line ART and Response to Second Line Treatment.
    AIDS Res Hum Retroviruses. 2020 Mar 5. doi: 10.1089/AID.2019.0232.
    >> Share

  89. MASOUD S, Kamori D, Godfrey B, Mahiti M, et al
    Circulating HIV-1 integrase genotypes in Tanzania: Implication on the introduction of Integrase Inhibitors-based ART regimen.
    AIDS Res Hum Retroviruses. 2020 Mar 4. doi: 10.1089/AID.2020.0021.
    >> Share

    January 2020
  90. LI X, Li H, Li C, Xia W, et al
    Traditional Chinese medicine can improve the immune reconstruction of HIV/AIDS patients.
    AIDS Res Hum Retroviruses. 2020 Jan 20. doi: 10.1089/AID.2019.0274.
    >> Share

  91. CICCULLO A, Baldin G, Lombardi F, Borghetti A, et al
    HIV DNA decay in a treatment-naive patient starting dolutegravir plus lamivudine with resistance mutations to integrase inhibitors: a case report.
    AIDS Res Hum Retroviruses. 2020 Jan 13. doi: 10.1089/AID.2019.0270.
    >> Share

  92. HERNANDEZ-SANCHEZ PG, Guerra-Palomares SE, Arguello JR, Noyola DE, et al
    Diversity of Mexican HIV-1 Protease Sequences.
    AIDS Res Hum Retroviruses. 2020 Jan 13. doi: 10.1089/AID.2019.0089.
    >> Share

  93. LAW JKC, Butler LT, Hamill MM
    Predictors of discontinuation of efavirenz as treatment for HIV, due to neuropsychiatric side effects, in a multi-ethnic sample in the UK.
    AIDS Res Hum Retroviruses. 2020 Jan 13. doi: 10.1089/AID.2019.0193.
    >> Share

  94. TAIWO B, Quinones-Mateu ME, Smith K, Zheng L, et al
    Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy.
    AIDS Res Hum Retroviruses. 2020 Jan 9. doi: 10.1089/AID.2019.0253.
    >> Share

    December 2019
  95. COUFFIGNAL C, Kolta S, Flamant M, Cazanave C, et al
    Nevirapine use is associated with higher bone mineral density in HIV-I positive patients on long-term antiretroviral therapy.
    AIDS Res Hum Retroviruses. 2019 Dec 31. doi: 10.1089/AID.2019.0229.
    >> Share

  96. ERLANDSON KM, Bradford Y, Samuels DC, Brown T, et al
    Mitochondrial DNA Haplogroups and Frailty in Adults Living with HIV.
    AIDS Res Hum Retroviruses. 2019 Dec 10. doi: 10.1089/AID.2019.0233.
    >> Share

    October 2019
  97. LU X, Zhang J, Wang Y, Liu M, et al
    Large transmission clusters of HIV-1 main genotypes among HIV-1 individuals before antiretroviral therapy in the Hebei province, China.
    AIDS Res Hum Retroviruses. 2019 Oct 9. doi: 10.1089/AID.2019.0199.
    >> Share

  98. CAMARGO CC, Cavassan NRV, Tasca KI, Meneguin S, et al
    Depression and Coping Are Associated with Failure of Adherence to Antiretroviral Therapy Among People Living with HIV/AIDS.
    AIDS Res Hum Retroviruses. 2019 Oct 8. doi: 10.1089/aid.2019.0050.
    >> Share

  99. HIRANSUTHIKUL A, Chutinet A, Sakulrak S, Samajarn J, et al
    Carotid intima-media thickness is not associated with neurocognitive impairment among people older than 50 years with and without HIV infection from Thailand.
    AIDS Res Hum Retroviruses. 2019 Oct 5. doi: 10.1089/AID.2019.0139.
    >> Share

  100. DE ARMAS L, Pallikkuth S, Rinaldi S, Pahwa R, et al
    Implications of Immune Checkpoint Expression during Aging for HIV-infected People on ART.
    AIDS Res Hum Retroviruses. 2019 Oct 3. doi: 10.1089/AID.2019.0135.
    >> Share

    September 2019
  101. SELLIER P, Hamet G, Brun A, Ponscarme D, et al
    Mortality of people living with HIV in Paris Area from 2011 to 2015.
    AIDS Res Hum Retroviruses. 2019 Sep 29. doi: 10.1089/AID.2019.0143.
    >> Share

  102. WU G, Zhou C, Zhang X, Zhang W, et al
    Higher risks of virologic failure and all-cause deaths among older people living with HIV in Chongqing, China.
    AIDS Res Hum Retroviruses. 2019 Sep 21. doi: 10.1089/AID.2019.0096.
    >> Share

  103. TEMEREANCA A, Ene L, Rosca A, Diaconu CC, et al
    Neurocognitive impairment in the cART era in a Romanian cohort of young adults with chronic HIV infection.
    AIDS Res Hum Retroviruses. 2019 Sep 3. doi: 10.1089/AID.2019.0132.
    >> Share

    August 2019
  104. CICCACCI F, Tolno VT, Doro Altan A, Liotta G, et al
    Non communicable diseases burden and risk factors in a cohort of HIV+ elderly patients in Malawi.
    AIDS Res Hum Retroviruses. 2019 Aug 30. doi: 10.1089/AID.2019.0125.
    >> Share

  105. RESSLER A, Abdo M, MaWhinney S, Johnson S, et al
    Examining Mortality To Identify Opportunities for Improved Care Among Adults with HIV in a Single Academic Medical Center.
    AIDS Res Hum Retroviruses. 2019 Aug 21. doi: 10.1089/AID.2019.0154.
    >> Share

    May 2019
  106. HUTCHINS E, Wang R, Rahmani S, Nakanishi R, et al
    HIV Infection is Associated with Greater Left Ventricular Mass in the Multicenter AIDS Cohort Study (MACS).
    AIDS Res Hum Retroviruses. 2019 May 2. doi: 10.1089/AID.2019.0014.
    >> Share

    May 2018
  107. LEWY T, Hong BY, Weiser B, Burger H, et al
    Oral microbiome in HIV-infected women: Shifts in the abundance of pathogenic and beneficial bacteria are associated with aging, HIV load, CD4 count, and ART.
    AIDS Res Hum Retroviruses. 2018 May 29. doi: 10.1089/AID.2017.0200.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016